| Similar Articles |
|---|
 |
The Motley Fool
August 9, 2007
Brian Lawler |
Depomed Is Distressed Depomed announces its distressing second-quarter financial results, with failed phase 3 studies and under-performing drugs.   |
The Motley Fool
January 19, 2011
Brian Orelli |
A Painfully Protracted Partner Depomed is in a bind. |
The Motley Fool
March 26, 2008
Brian Lawler |
Take Two for Depomed The pharmaceutical starts another study for its proposed pain drug. The new study will double the size of patients enrolled and help reduce placebo effects. |
The Motley Fool
June 22, 2010
Dave Mock |
A Big Upgrade for DepoMed This bullish call comes from more than just one analyst. |
The Motley Fool
July 11, 2007
Brian Lawler |
Why Depomed Shares Were Dumped In a recent trial, a pain medication wasn't as effective as had been hoped. Investors, take note. |
The Motley Fool
December 28, 2004
Charly Travers |
It's All in the Delivery If too much risk makes you queasy, these drug companies are for you. SkyePharma... DepoMed... |
The Motley Fool
September 20, 2007
Brian Lawler |
Allergan's Overactive Acquisition Specialty pharma Allergan announced yesterday that it is acquiring privately held Esprit Pharma for $370 million in an all-cash transaction. Investors, take note. |
The Motley Fool
January 31, 2011
Brian Orelli |
Drug Approved! Now Who's Going to Launch It? Depomed gets pain-free news from the FDA. |
The Motley Fool
May 16, 2007
Mike Havrilla |
Biotech Prospects for a Sizzling Summer Consider these biotech stocks to make your portfolio sizzle this summer. Advanced Life Sciences... Depomed... Theravance... etc. |
The Motley Fool
April 7, 2011
Brian Orelli |
Restless No Longer XenoPort and Glaxo get a delayed FDA approval. |
The Motley Fool
August 3, 2007
Brian Orelli |
Watson Turns It Around The pharmaceutical's steady revenue growth results in positive income for the quarter. Investors, take note. |
